In a Phase II study of AFM13 monotherapy in patients with CD30+ R/R PTCL, among 108 patients, the ORR was 32.4% with a CRR of 10.2%. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.